Press releases
- Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
- Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
- Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
- Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
- Cerus Corporation to Participate in Upcoming Investor Conferences
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.45 |
---|---|
High | 4.45 |
Low | 4.45 |
Bid | 4.40 |
Offer | 4.48 |
Previous close | 4.45 |
Average volume | -- |
---|---|
Shares outstanding | 181.28m |
Free float | 176.69m |
P/E (TTM) | -- |
Market cap | 297.30m USD |
EPS (TTM) | -0.2086 USD |
Data delayed at least 15 minutes, as of Aug 24 2022.
More ▼